Document is current

Article History

Received: 26 December 2025

Accepted: 24 June 2026

First Online: 29 June 2026

Declarations

:

: Shinichiro Shinzaki received research grants from AbbVie, JIMRO, Nippon Kayaku, Zeria Pharmaceutical, EA Pharma, Kyorin Pharmaceutical, and Mochida Pharmaceutical, serves as a consultant to AbbVie, Celltrion Healthcare, Eli Lilly, Janssen Pharmaceutical, Sekisui Medical, Bristol Myers Squibb, EA Pharma, Gilead Sciences, Kissei Pharmaceutical, and Takeda Pharmaceutical, and received lecture fees from AbbVie, Celltrion Healthcare, EA Pharma, Gilead Sciences, Janssen Pharmaceutical, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, and Sekisui Medical; Katsuyoshi Matsuoka received research grants from EA Pharma, Mochida Pharmaceutical, and AbbVie, serves as a consultant to Eli Lilly, Takeda Pharmaceutical, Pfizer, and MSD, received lecture fees from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Janssen Pharmaceutical, AbbVie, EA Pharma, Pfizer, Mochida Pharmaceutical, Kyorin Pharmaceutical, Zeria Pharmaceutical, Kissei Pharmaceutical, Gilead Sciences, Celltrion Healthcare, Eli Lilly, and GlaxoSmithKline; Mikihiro Fujiya received research grants from EA Pharma, AYUMI Pharmaceutical, AbbVie, Otsuka Pharmaceutical, Zeria Pharmaceutical, Nippon Kayaku, Nobelpharma, Pfizer, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical, received lecture fees from EA Pharma, AYUMI Pharmaceutical, AbbVie, Otsuka Pharmaceutical, Zeria Pharmaceutical, JIMRO, Nippon Kayaku, Nobelpharma, Pfizer, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Daiichi Sankyo, and Mitsubishi Tanabe Pharma, and owns stock in Kamui Pharma; Sakiko Hiraoka received lecture fees from AbbVie, EA Pharma, Kyorin Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, and Janssen Pharmaceutical; Takayuki Matsumoto received lecture fees from Janssen Pharmaceutical and Gilead Sciences; Shin-ichiro Hagiwara received lecture fees from AbbVie, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, and Alfresa Pharma; Hirotake Sakuraba received research grants from Yakult Honsha and AbbVie, and received lecture fees from AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, and EA Pharma; Makoto Naganuma received research grants from AbbVie and Mochida Pharmaceutical, and received lecture fees from EA Pharma, Gilead Sciences, Takeda Pharmaceutical, AbbVie, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, and Pfizer; Tomohisa Takagi received research grants from PreMedica, Mitsubishi Tanabe Pharma, and AMED, and received lecture fees from Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Towa Pharmaceutical, Mochida Pharmaceutical, Takeda Pharmaceutical, AbbVie, EA Pharma, and Pfizer; Tadakazu Hisamatsu received research grants from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, EA Pharma, AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Nippon Kayaku, Pfizer, Boston Scientific, and Mochida Pharmaceutical, serves as a consultant to EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, JIMRO, Mochida Pharmaceutical, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, and Abivax, and received lecture fees from EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, JIMRO, Mochida Pharmaceutical, Bristol Myers Squibb, Eli Lilly, and Gilead Sciences.